



22

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of :
Ulrich KLAR et al. : Group Art Unit.: 1626
Serial No.: 10/631,011 : Examiner: Taofiq A. Solola
Filed: July 31,2003 :

Title: EFFECTOR CONJUGATES, PROCESS FOR THEIR PRODUCTION AND THEIR
PHARMACEUTICAL USE

REPLY


Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SIR:

In response to the Office Action mailed on July 21, 2005, the identity of each subsituent on the elected species is identified below:

R^{1a}, R^{1b} are both C₁-alkyl,
R^{2a}, R^{2b} one is a hydrogen and the other is a C₃-alkenyl,
R³ is hydrogen,
R^{4a}, R^{4b}, one is a hydrogen and the other is a C₁-alkyl,
R⁵ is a C₁-alkyl,
R⁶, R⁷ in together an oxygen atom,
G is CH₂,
D-E is a group H₂C-CH₂,
W is a bicyclic heteroaromatic radical, which is a 2-methylbenzothiazol-5-yl radical,
L³ is hydrogen,
Z is oxygen,
A-Y is O-C(=O),
L¹ is hydrogen,
L², is a linker of general formula (IV);
T is oxygen,
W¹, W² are both oxygen,
o is 1,

R²⁷ is NO₂,
q is 0,
U is C₃-alkyl,
r is 0,
FG¹ is replaced by a group FG^{2a},
FG^{2a} is




, and

the recognition unit is a monoclonal antibody.

The Commissioner is hereby authorized to charge any fees associated with this response or credit any overpayment to Deposit Account No. 13-3402.

Respectfully submitted,



Csaba Henter, Reg. No. 50,908
Anthony J. Zelano Reg. No. 27,969
Attorney for Applicant(s)

MILLEN, WHITE, ZELANO
& BRANIGAN, P.C.
Arlington Courthouse Plaza 1, Suite 1400
2200 Clarendon Boulevard
Arlington, Virginia 22201
Telephone: (703) 243-6333
Facsimile: (703) 243-6410

Attorney Docket No.: SCH-2049

Date: July 26, 2005

K:\Sch\2049\Reply 2nd to Restr.doc